|
1.
|
|
19 p, 1.5 MB |
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
/
Wieduwilt, M.J. (University of Oklahoma) ;
Metheny, L. (University Hospitals Seidman Cancer Center) ;
Zhang, M.J. (Medical College of Wisconsin) ;
Wang, H.L. (Center for International Blood and Marrow Transplant Research) ;
Estrada-Merly, N. (Center for International Blood and Marrow Transplant Research) ;
Marks, D.I. (University Hospitals Bristol National Health Service Trust) ;
Samer Al-Homsi, A. (New York University Langone Health) ;
Muffly, L. (Stanford University) ;
Chao, N. (Duke University Medical Center) ;
Rizzieri, D. (Duke University) ;
Gale, R.P. (Imperial College London) ;
Gadalla, S.M. (National Institutes of Health) ;
Cairo, M. (New York Medical College) ;
Mussetti, Alberto (Institut d'Investigacio Biomedica de Bellvitge) ;
Gore, S. (Yale New Haven Hospital) ;
Bhatt, V.R. (University of Nebraska Medical Center) ;
Patel, S.S. (University of Utah) ;
Michelis, F.V. (Princess Margaret Cancer Centre) ;
Inamoto, Y. (National Cancer Center Hospital) ;
Badawy, S.M. (Northwestern University Feinberg School of Medicine) ;
Copelan, E. (Atrium Health) ;
Palmisiano, N. (Thomas Jefferson University) ;
Kharfan-Dabaja, M.A. (Mayo Clinic) ;
Lazarus, H.M. (Case Western Reserve University) ;
Ganguly, S. (University of Kansas Health System) ;
Bredeson, C. (The Ottawa Hospital Transplant and Cellular Therapy Program) ;
Perez, M.A.D. (Hospital Infantil Universitario Niño Jesus) ;
Cassaday, R. (University of Washington) ;
Savani, B.N. (Vanderbilt University Medical Center) ;
Ballen, K. (Division of Hematology/Oncology. University of Virginia Health System) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Wirk, B. (Penn State Cancer Institute) ;
Bacher, U. (University of Bern) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital Center and Research) ;
Bashey, A. (Northside Hospital) ;
Murthy, H.S. (Mayo Clinic) ;
Yared, J.A. (University of Maryland) ;
Aldoss, I. (City of Hope Medical Center) ;
Farhadfar, N. (University of Florida College of Medicine) ;
Liu, H. (University of Chicago Medicine) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Waller, E.K. (Emory University) ;
Solh, M. (Northside Hospital) ;
Seftel, M.D. (University of British Columbia) ;
van der Poel, M. (Maastricht University Medical Center) ;
Grunwald, M.R. (Atrium Health) ;
Liesveld, J.L. (University of Rochester Medical Center) ;
Kamble, R.T. (Baylor College of Medicine) ;
McGuirk, J. (University of Kansas Health System) ;
Munker, R. (University of Kentucky) ;
Cahn, J.Y. (Universite Grenoble Alpes) ;
Lee, J.W. (The Catholic University of Korea) ;
Freytes, C.O. (University of Texas Health Science Center) ;
Krem, M.M. (University of Kentucky) ;
Winestone, L.E. (University of California) ;
Gergis, U. (Thomas Jefferson University) ;
Nathan, S. (Rush University Medical Center) ;
Olsson, R.F. (Karolinska Institutet) ;
Verdonck, L.F. (Isala Clinic) ;
Sharma, A. (St. Jude Children's Research Hospital) ;
Ringden, O. (Karolinska Institutet) ;
Friend, B.D. (Baylor College of Medicine) ;
Cerny, J. (University of Massachusetts Medical Center) ;
Choe, H. (The Ohio State University Wexner Medical Center) ;
Chhabra, S. (Center for International Blood and Marrow Transplant Research) ;
Nishihori, T. (Moffitt Cancer Center) ;
Seo, S. (Dokkyo Medical University) ;
George, B. (Christian Medical College) ;
Baxter-Lowe, L.A. (Children's Hospital Los Angeles) ;
Hildebrandt, G.C. (University of Kentucky) ;
de Lima, M. (University Hospitals Case Medical Center) ;
Litzow, M. (Mayo Clinic Rochester) ;
Kebriaei, P. (The University of Texas MD Anderson Cancer Center) ;
Hourigan, C.S. (National Institutes of Health) ;
Abid, M.B. (Medical College of Wisconsin) ;
Weisdorf, D.J. (University of Minnesota) ;
Saber, W. (Center for International Blood and Marrow Transplant Research) ;
Universitat Autònoma de Barcelona
The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. [...]
2022 -  10.1182/bloodadvances.2021004916
Blood advances, Vol. 6 Núm. 1 (november 2022) , p. 339-357
|
|
|
2.
|
|
34 p, 950.5 KB |
Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies
/
Pasquini, Marcelo (Medical College of Wisconsin) ;
Zhang, Mei-Jie (Medical College of Wisconsin) ;
Medeiros, Bruno (Stanford University School of Medicine) ;
Armand, Philippe (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Hu, Zhen-Huan (Medical College of Wisconsin) ;
Nishihori, Taiga (H. Lee Moffitt Cancer Center and Research Institute) ;
Aljurf, Mahmoud D. (King Faisal Specialist Hospital Center and Research) ;
Akpek, Görgün (Banner MD Anderson Cancer Center) ;
Cahn, Jean-Yves (University Hospital) ;
Cairo, Mitchell S. (New York Medical College) ;
Cerny, Jan (UMass Memorial Medical Center) ;
Copelan, Edward A. (Carolinas HealthCare System) ;
Deol, Abhinav (Wayne State University) ;
Freytes, César O. (University of Texas Health Science Center San Antonio) ;
Gale, Robert Peter (Imperial College London) ;
Ganguly, Siddhartha (University of Kansas Medical Center) ;
George, Biju (Christian Medical College) ;
Gupta, Vikas (University Health Network) ;
Hale, Gregory A. (All Children's Hospital) ;
Kamble, Rammurti T. (Baylor College of Medicine) ;
Klumpp, Thomas R. (Thomas Jefferson University Hospital) ;
Lazarus, Hillard M. (University Hospitals Case Medical Center) ;
Luger, Selina M. (University of Pennsylvania Medical Center) ;
Liesveld, Jane L. (University of Rochester Medical Center) ;
Litzow, Mark Robert (Mayo Clinic) ;
Marks, David I. (University Hospitals Bristol NHS Trust) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Norkin, Maxim (University of Florida College of Medicine) ;
Olsson, Richard F. (Uppsala University) ;
Oran, Betul (The University of Texas MD Anderson Cancer Center) ;
Pawarode, Attaphol (University of Michigan) ;
Pulsipher, Michael A. (University of Southern California Keck School of Medicine) ;
Ramanathan, Muthalagu (UMass Memorial Medical Center) ;
Reshef, Ran (University of Pennsylvania Medical Center) ;
Saad, Ayman A. (University of Alabama at Birmingham) ;
Saber, Wael (Medical College of Wisconsin) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Schouten, Harry C. (Academische Ziekenhuis) ;
Ringdén, Olle (Centre for Allogeneic Stem Cell Transplantation) ;
Tallman, Martin S. (Memorial Sloan Kettering Cancer Center) ;
Uy, Geoffrey L. (Washington University School of Medicine) ;
Wood, William A. (University of North Carolina) ;
Wirk, Baldeep (Seattle Cancer Care Alliance) ;
Pérez, Waleska S. (Medical College of Wisconsin) ;
Batiwalla, Minoo (National Heart Lung and Blood Institute - National Institutes of Health) ;
Weisdorf, Daniel J. (University of Minnesota Medical Center) ;
Universitat Autònoma de Barcelona
The presence of monosomal karyotype (MK+) in acute myeloid leukemia (AML) is associated with dismal outcomes. We evaluated the impact of MK+ in AML (MK+AML, n = 240) and in myelodysplastic syndrome (MDS) (MK+MDS, n = 221) on hematopoietic cell transplantation outcomes compared with other cytogenetically defined groups (AML, n = 3360; MDS, n = 1373) as reported to the Center for International Blood and Marrow Transplant Research from 1998 to 2011. [...]
2016 - 10.1016/j.bbmt.2015.08.024
Biology of blood and marrow transplantation, Vol. 22 Núm. 2 (january 2016) , p. 248-257
|
|
|
3.
|
|
11 p, 547.4 KB |
Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation
/
Bejanyan, Nelli (University of Minnesota) ;
Zhang, Mei-Jie (Medical College of Wisconsin) ;
Wang, Hai-Lin (Medical College of Wisconsin) ;
Lazaryan, Aleksandr (University of Minnesota) ;
de Lima, Marcos (University Hospitals Case Medical Center) ;
Marks, David I. (University Hospitals Bristol NHS Trust) ;
Sandmaier, Brenda M. (Fred Hutchinson Cancer Research Center) ;
Bachanova, Veronika (University of Minnesota) ;
Rowe, Jacob (Shaare Zedek Medical Center) ;
Tallman, Martin (Memorial Sloan Kettering Cancer Center) ;
Kebriaei, Partow (The University of Texas MD Anderson Cancer Center) ;
Kharfan-Dabaja, Mohamed (H. Lee Moffitt Cancer Center and Research Institute) ;
Peter Gale, Robert (Imperial College London) ;
Lazarus, Hillard M. (University Hospitals Cleveland Medical Center) ;
Ustun, Celalettin (University of Minnesota) ;
Copelan, Edward (Carolinas HealthCare System) ;
Ky Hamilton, Betty (Cleveland Clinic Taussig Cancer Institute) ;
Schiller, Gary (David Geffen School of Medicine at UCLA) ;
Hogan, Willian (Mayo Clinic Rochester) ;
Hashmi, Shahrukh (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
Seftel, Matthew (CancerCare Manitoba) ;
Kanakry, Christopher G. (National Institutes of Health (Bethesda, Estats Units d'Amèrica)) ;
Olsson, Richard F. (Uppsala University) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Saber, Wael (Medical College of Wisconsin) ;
Khoury, H.Jean (Emory University Hospital) ;
Weisdorf, Daniel J. (University of Minnesota) ;
Universitat Autònoma de Barcelona
Allogeneic hematopoietic cell transplantation (alloHCT) is curative for patients with acute lymphoblastic leukemia (ALL) who achieve complete remission (CR1) with chemotherapy. However, the benefit of consolidation chemotherapy remains uncertain in patients undergoing alloHCT. [...]
2018 - 10.1016/j.bbmt.2017.12.784
Biology of blood and marrow transplantation, Vol. 24 Núm. 5 (may 2018) , p. 945-955
|
|
|
4.
|
|
9 p, 406.9 KB |
Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation
/
Saad, Ayman (The Ohio State University) ;
Lamb, Lawrence (University of Alabama at Birmingham) ;
Wang, Tao (Medical College of Wisconsin) ;
Hemmer, Michael T. (Medical College of Wisconsin) ;
Spellman, Stephen (National Marrow Donor Program/Be the Match) ;
Couriel, Daniel R (Utah Blood and Marrow Transplant Program) ;
Alousi, Amin (Anderson Cancer Center) ;
Pidala, Joseph (H. Lee Moffitt Cancer Center) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Agrawal, Vaibhav (Indiana University School of Medicine) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
Beitinjaneh, Amer (University of Miami) ;
Bhatt, Vijaya Raj (University of Nebraska Medical Center) ;
Buchbinder, David Kyle (Children's Hospital of Orange County) ;
Byrne, Michael (Vanderbilt University Medical Center) ;
Cahn, Jean-Yves (CHU Grenoble Alpes) ;
Cairo, Mitchell S. (New York Medical College) ;
Castillo, Paul A. (UF Health Shands Children's Hospital) ;
Chhabra, Saurabh (Medical College of Wisconsin) ;
Diaz, Miguel Angel (Hospital Infantil Universitario Nino Jesus) ;
Farhan, Shatha (Henry Ford Hospital Bone Marrow Transplant Program) ;
Floisand, Yngvar (The National Hospital) ;
Frangoul, Haydar A. (Children's Hospital at TriStar Centennial and Sarah Cannon Research Institute) ;
Gadalla, Shahinaz M. (National Cancer Institute) ;
Gajewski, James (Consultant at Lu Daopei Hospital) ;
Gale, Robert Peter (Imperial College London) ;
Gandhi, Manish (Mayo Clinic) ;
Gergis, Usama (New York Presbyterian Hospital/Weill Cornell Medical Center) ;
Hamilton, Betty (Cleveland Clinic Taussig Cancer Institute) ;
Hematti, Peiman (University of Wisconsin Hospital and Clinics) ;
Hildebrandt, Gerhard C. (University of Kentucky) ;
Kamble, Rammurti T. (Baylor College of Medicine) ;
Kanate, Abraham S. (West Virginia University) ;
Khandelwal, Pooja (Cincinnati Children's Hospital Medical Center) ;
Lazaryn, Aleksandr (H. Lee Moffitt Cancer Center) ;
MacMillan, Margaret (University of Minnesota Blood and Marrow Transplant Program) ;
Marks, David I. (University Hospitals Bristol NHS Trust) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Mehta, Parinda A. (Cincinnati Children's Hospital Medical Center) ;
Nishihori, Taiga (H. Lee Moffitt Cancer Center) ;
Olsson, Richard (Uppsala University) ;
Patel, Sagar (Cleveland Clinic Foundation) ;
Qayed, Muna (Emory University School of Medicine) ;
Rangarajan, Hemalatha G. (Nationwide Children's Hospital) ;
Reshef, R. (Columbia University Medical Center) ;
Ringden, O. (Karolinska Institutet (Estocolm, Suècia)) ;
Savani, B.N. (Vanderbilt University Medical Center) ;
Schouten, H.C. (Academische Ziekenhuis) ;
Schultz, K.R. (The University of British Columbia) ;
Seo, S. (Dokkyo Medical University) ;
Shaffer, B.C. (Memorial Sloan Kettering Cancer Center) ;
Solh, M. (Northside Hospital) ;
Teshima, T. (Hokkaido University Hospital) ;
Urbano-Ispizua, Alvaro (Hospital Clínic i Provincial de Barcelona) ;
Verdonck, L.F. (Isala Clinic) ;
Vij, R. (Washington University School of Medicine) ;
Waller, E.K. (Emory University) ;
William, B. (The Ohio State University) ;
Wirk, B. (Seattle Cancer Care Alliance) ;
Yared, J.A. (University of Maryland) ;
Yu, L.C. (Children's Hospital/Louisiana State University Medical Center) ;
Arora, M. (University of Minnesota Medical Center) ;
Hashmi, S. (Mayo Clinic) ;
Universitat Autònoma de Barcelona
Data on whether the T cell dose of allogeneic peripheral blood stem cell (PBSC) products influences transplantation outcomes are conflicting. Using the Center for International Blood and Marrow Transplant Research database, we identified 2736 adult patients who underwent first allogeneic PBSC transplantation for acute leukemia or myelodysplastic syndrome between 2008 and 2014 using an HLA-matched sibling donor (MSD) or an 8/8-matched unrelated donor (MUD). [...]
2019 - 10.1016/j.bbmt.2019.05.007
Biology of blood and marrow transplantation, Vol. 25 Núm. 9 (september 2019) , p. 1875-1883
|
|
|
5.
|
|
8 p, 930.0 KB |
Ruxolitinib in refractory acute and chronic graft-versus-host disease : a multicenter survey study
/
Escamilla Gómez, V. (Universidad de Sevilla) ;
García-Gutiérrez, Valentín (University Hospital Ramon y Cajal) ;
López Corral, Lucía (Complejo Asistencial Universitario de Salamanca-IBSAL) ;
Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
Pérez Martínez, Ariadna (Hospital Clínic Universitari (València)) ;
Márquez Malaver, F.J. (Universidad de Sevilla) ;
Caballero Velazquez, Teresa (Universidad de Sevilla) ;
González Sierra, P.A. (Hospital Universitario (Granada)) ;
Viguria Alegría, M.C. (Complejo Hospitalario de Navarra) ;
Parra Salinas, I.M. (Hospital Universitario Miguel Servet (Saragossa)) ;
Calderón Cabrera, C. (Universidad de Sevilla) ;
González Vicent, M. (Hospital Infantil Universitario Niño Jesús (Madrid)) ;
Rodríguez Torres, N. (Universidad de Sevilla) ;
Parody Porras, R. (Instituto Catalá de Oncología Hospitalet) ;
Ferrá, Christelle (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Orti, Guillermo (Hospital Universitari Vall d'Hebron) ;
Valcárcel Ferreiras, D. (Hospital Universitari Vall d'Hebron) ;
de la Camara, Rafael (Hospital Universitario de la Princesa (Madrid)) ;
Molés, P. (Hospital Universitari i Politècnic La Fe (València)) ;
Velázquez-Kennedy, K. (Hospital Universitari Ramon y Cajal) ;
João Mende, M. (Complejo Asistencial Universitario de Salamanca-IBSAL) ;
Caballero, Dolores (Complejo Asistencial Universitario de Salamanca-IBSAL) ;
Pérez, Estefanía (Complejo Asistencial Universitario de Salamanca-IBSAL) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Saavedra Gerosa, Silvana Daniela (Institut d'Investigació Biomèdica Sant Pau) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Poch, M. (Clinic Hospital Universitari de Valencia) ;
Zudaire Ripa, M.T. (Complejo Hospitalario de Navarra) ;
Díaz Pérez, M.A. (Hospital Infantil Universitario Niño Jesús (Madrid)) ;
Molina Angulo, B. (Hospital Infantil Universitario Niño Jesús (Madrid)) ;
Sánchez Ortega, I. (Instituto Catalá de Oncología Hospitalet) ;
Sanz Caballer, J. (Hospital Universitari i Politècnic La Fe (València)) ;
Montoro Gómez, J. (Hospital Universitari i Politècnic La Fe (València)) ;
Espigado Tocino, I. (Universidad de Sevilla) ;
Pérez-Simón, J.A. (Universidad de Sevilla) ;
Universitat Autònoma de Barcelona
Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. [...]
2020 - 10.1038/s41409-019-0731-x
Bone marrow transplantation, Vol. 55 Núm. 3 (january 2020) , p. 641-648
|
|
|
6.
|
|
13 p, 1009.5 KB |
Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days after Allogeneic Hematopoietic Stem Cell Transplant
/
Dandoy, C.E. (Cincinnati Children's Hospital Medical Center) ;
Kim, S. (Medical College of Wisconsin) ;
Chen, M. (Medical College of Wisconsin) ;
Ahn, Kwang Woo (Medical College of Wisconsin) ;
Ardura, M.I. (Nationwide Children's Hospital) ;
Brown, V. (Penn State Hershey Children's Hospital) ;
Chhabra, Saurabh (Medical College of Wisconsin) ;
Diaz, M.A. (Hospital Infantil Universitario Nino Jesus) ;
Dvorak, C. (University of California) ;
Farhadfar, N. (University of Florida) ;
Flagg, A. (Yale New Haven Hospital) ;
Ganguly, S. (University of Kansas Health System) ;
Hale, G.A. (Johns Hopkins All Children's Hospital) ;
Hashmi, S.K. (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
Hematti, Peiman (University of Wisconsin) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Nishihori, T. (Lee Moffitt Cancer Center and Research Institute) ;
Nusrat, R. (Rutgers Robert Wood Johnson Medical School) ;
Olsson, R.F. (Uppsala University) ;
Rotz, S.J. (Cleveland Clinic Children's Hospital) ;
Sung, A.D. (Duke University School of Medicine) ;
Perales, M.A. (Memorial Sloan Kettering Cancer Center) ;
Lindemans, C.A. (Princess Maxima Center for Pediatric Oncology) ;
Komanduri, K.V. (University of Miami) ;
Riches, M.L. (University of North Carolina at Chapel Hill) ;
Universitat Autònoma de Barcelona
Importance: Patients undergoing hematopoietic stem cell transplant (HSCT) are at risk for bloodstream infection (BSI) secondary to translocation of bacteria through the injured mucosa, termed mucosal barrier injury-laboratory confirmed bloodstream infection (MBI-LCBI), in addition to BSI secondary to indwelling catheters and infection at other sites (BSI-other). [...]
2020 - 10.1001/jamanetworkopen.2019.18668
JAMA network open, Vol. 3 Núm. 1 (2020) , p. e1918668
|
|
|
7.
|
|
13 p, 850.9 KB |
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation
/
Chhabra, Saurabh (Medical College of Wisconsin) ;
Liu, Ying (Medical College of Wisconsin) ;
Hemmer, Michael T. (Medical College of Wisconsin) ;
Costa, Luciano (University of Alabama at Birmingham. Department of Medicine) ;
Pidala, Joseph A. (H. Lee Moffitt Cancer Center and Research Institute) ;
Couriel, Daniel R. (Utah Blood and Marrow Transplant Program) ;
Alousi, Amin M. (University of Texas MD Anderson Cancer Center) ;
Majhail, Navneet S. (Cleveland Clinic Taussig Cancer Institute) ;
Stuart, Robert K. (Medical University of South Carolina) ;
Kim, Dennis (Princess Margaret Cancer Center) ;
Ringden, Olle (Karolinska Institutet (Estocolm, Suècia). Division of Therapeutic Immunology) ;
Urbano Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Saad, Ayman (University of Alabama at Birmingham) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Cooper, Brenda (University Hospitals Case Medical Center. Department of Medicine-Hematology and Oncology) ;
Marks, David I. (University Hospitals Bristol NHS Trust) ;
Socie, Gerard (Hôpital Saint Louis. Department of Hematology) ;
Schouten, Harry C. (Academische Ziekenhuis. Department of Hematology) ;
Schoemans, Helene (University Hospitals Leuven (Bèlgica)) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Yared, Jean (University of Maryland. Greenebaum Cancer Center) ;
Cahn, Jean-Yves (CHU Grenoble Alpes. Department of Hematology) ;
Wagner, John (Thomas Jefferson University. Department of Medical Oncology) ;
Antin, Joseph H. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Verdonck, Leo F. (Isala Clinic. Departmentt of Hematology/Oncology) ;
Lehmann, Leslie (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
MacMillan, Margaret L. (University of Minnesota Blood and Marrow Transplant Program) ;
Litzow, Mark R. (Mayo Clinic Rochester. Division of Hematology and Transplant Center) ;
Solh, Melhem M. (Northside Hospital. Blood and Marrow Transplant Group of Georgia) ;
Qayed, Muna (Emory University School of Medicine. Department of Pediatrics) ;
Hematti, Peiman (University of Wisconsin) ;
Kamble, Rammurti T. (Baylor College of Medicine) ;
Vij, Ravi (Washington University School of Medicine. Division of Hematology and Oncology) ;
Hayashi, Robert J. (Washington University School of Medicine in St. Louis. Division of Pediatric Hematology/Oncology) ;
Gale, Robert Peter (Imperial College London. Hematology Research Centre) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Seo, Sachiko (National Cancer Research Center East) ;
Hashmi, Shahrukh K (Mayo Clinic Rochester. Division of Hematology and Transplant Center) ;
Nishihori, Taiga (H. Lee Moffitt Cancer Center and Research Institute) ;
Teshima, Takanori (Kyushu University Hospital) ;
Gergis, Usama (New York Presbyterian Hospital/Weill Cornell Medical Center. Department of Medical Oncology) ;
Inamoto, Yoshihiro (National Cancer Center Hospital) ;
Spellman, Stephen R. (Center for International Blood and Marrow Transplant Research) ;
Arora, Mukta (University of Minnesota Medical Center) ;
Hamilton, Betty K. (Cleveland Clinic Taussig Cancer Institute) ;
Universitat Autònoma de Barcelona
The combination of a calcineurin inhibitor (CNI) such as tacrolimus (TAC) or cyclosporine (CYSP) with methotrexate (MTX) or with mycophenolate mofetil (MMF) has been commonly used for graft-versus-host disease (GVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT), but there are limited data comparing efficacy of the 2 regimens. [...]
2019 - 10.1016/j.bbmt.2018.08.018
Biology of blood and marrow transplantation, Vol. 25 Núm. 1 (january 2019) , p. 73-85
|
|
|
8.
|
|
16 p, 1.5 MB |
Risk factors and outcome of COVID-19 in patients with hematological malignancies
/
Piñana, José Luis (Hospital Universitari i Politècnic La Fe (València)) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
García-García, Irene (Hospital Universitario Ramón y Cajal (Madrid)) ;
Parody Porras, Rocío (Institut Català d'Oncologia) ;
Morales, María Dolores (Hematology División. Hospital de Guadalajara) ;
Benzo, Gonzalo (Hospital Universitario de la Princesa (Madrid)) ;
Gómez-Catalan, Irene (Complejo Hospitalario Universitario de Albacete) ;
Coll, Rosa (Hospital Universitari de Girona Doctor Josep Trueta) ;
De La Fuente, Ignacio (Hospital Clínico Universitario de Valladolid) ;
Luna, Alejandro (Hospital Universitario Ramón y Cajal (Madrid)) ;
Merchán, Beatriz (Hematology División. Hospital de Guadalajara) ;
Chinea, Anabelle (Hospital Universitario Ramón y Cajal (Madrid)) ;
De Miguel, Dunia (Hematology División. Hospital de Guadalajara) ;
Serrano, Ana (Complejo Hospitalario Universitario de Albacete) ;
Pérez, Carmen (Hospital Clínico Universitario de Valladolid) ;
Diaz, Carola (Hospital Regional Universitario Carlos Haya (Málaga)) ;
Lopez, José Luis (Hospital Universitario Fundación Jiménez Díaz) ;
Saez, Adolfo Jesús (Hospital Universitario Ramón y Cajal (Madrid)) ;
Bailén, Rebeca (Hospital General Universitario Gregorio Marañón) ;
Zudaire, Teresa (Complejo Hospitalario de Navarra) ;
Martínez, Diana (Complejo Hospitalario Universitario de A Coruña) ;
Jurado, Manuel (Hospital Universitario Virgen de las Nieves (Granada)) ;
Calbacho, Maria (Hospital Universitario 12 de Octubre (Madrid)) ;
Vázquez, Lourdes (Hospital Universitario de Salamanca) ;
Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
Fox, Maria Laura (Vall d'Hebron Institut d'Oncologia) ;
Pimentel, Ana I. (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Bautista, Guiomar (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Nieto, Agustín (Complexo Hospitalario Universitario de Vigo) ;
Fernandez, Pascual (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Vallejo, Juan Carlos (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) ;
Solano, Carlos (Hospital Clínic Universitari (València)) ;
Valero, Marta (Hospital Arnau de Vilanova (Lleida, Catalunya)) ;
Espigado, Ildefonso (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Saldaña, Raquel (Hospital Universitario de Jerez (Jerez de la Frontera)) ;
Sisinni, Luisa (Hospital Universitario La Paz (Madrid)) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Jiménez, María José (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Trabazo del Castillo, María (Institut d'Investigació Biomèdica Sant Pau) ;
González Vicent, Marta (Hospital Infantil Universitario Niño Jesús (Madrid)) ;
Fernández, Noemí (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Talarn, Carme (Hospital Universitari Joan XXIII de Tarragona) ;
Montoya, Maria Carmen (Complejo Hospitalario Universitario de Albacete) ;
Cedillo, Angel (Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)) ;
Sureda, Anna (Institut Català d'Oncologia) ;
Universitat Autònoma de Barcelona
Background: Prognostic factors of poor outcome in patients with hematological malignancies and COVID-19 are poorly defined. Patients and methods: This was a Spanish transplant group and cell therapy (GETH) multicenter retrospective observational study, which included a large cohort of blood cancer patients with laboratory-confirmed SARS-CoV-2 infection through PCR assays from March 1st 2020 to May 15th 2020. [...]
2020 - 10.1186/s40164-020-00177-z
Experimental Hematology & Oncology, Vol. 9 Núm. 1 (25 2020) , p. 21
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
